霍奇金淋巴瘤治疗进展：第54届美国血液学会年会深度报道  

Report on recent treatment of Hodgkin＇ s lymphoma in the 54th ASH annual meeting

作　　者：邹志建[1] 徐卫[1] 李建勇[1] 

机构地区：[1]南京医科大学第一附属医院江苏省人民医院血液科 ,210029

出　　处：《白血病．淋巴瘤》2013年第1期21-24,共4页Journal of Leukemia & Lymphoma

摘　　要：目前，早期霍奇金淋巴瘤（HL）可通过化疗联合受累野放疗或单纯化疗的方式被治愈，但对放疗在早期HL治疗中的必要性仍有争议。而复发、难治HL的治疗仍存在着巨大挑战，除了大剂量化疗序贯自体造血干细胞移植外，尚缺乏有效的治疗手段。安全有效的新型药物如brentuximabvedotin的应用将有助于改善这类患者的生存预后。中期PET（PET—i）检查对早期和晚期HL患者都具有重要预后价值，尤其是在化疗2个周期后行PET检查，但依据PET—i结果而改变治疗方法除临床试验外并不被推荐。Early stage Hodgkin＇ s lymphoma （HL） is highly curable with abbreviated chemotherapy plus involved-filed radiotherapy or chemotherapy alone, but the role of radiation remains the subject of debate and disagreement. The management of recurrent or refractory HL remains challenging with limited effective treatments except high dose therapy with autologous stem cell transplantation. Emerging new safe and effective drugs such as brentuximab vedotin might promisingly improve the outcome of these patients in the future. The interim positron emission tomography （PET-i） scan has important prognostic value in patients with early and advanced stage HL, especially PET scan after 2 cycles. However, the PET-i guided treatment decisions are not currently recommended outside clinical trials.

关 键 词：淋巴瘤 霍奇金 治疗 美国血液学会年会 

分 类 号：R733.1[医药卫生—肿瘤]